drugset / Trial / NCT05350787

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

NCT05350787

Phase 1 Completed 10 enrolled Zhejiang University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with relapsed and refractory acute B-cell leukemia

Timeline

Start
2022-03-18
Primary completion
2025-05-21
Completion
2025-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ThisCART19A Cell therapy 3 cells/kg
Subject ThisCART19A Cell therapy 5 cells/kg

Indications

No indication recorded.